Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...
“We continue to see mass destruction”: Reporter details wildfire impact in Altadena
NBC News' Liz Kreutz reports on the destruction in the Altadena area of Los Angeles due to the extensive wildfires.